Form 4: United Therapeutics Director Exercises Stock Options and Sells Shares

Christopher Patusky, a director at United Therapeutics Corp, exercised stock options and sold shares on May 14, 2024.

Summary

• On May 14, 2024, Christopher Patusky, a director at United Therapeutics Corp, exercised stock options for 1,310 shares of common stock at a price of $76.36.
• Simultaneously, Patusky sold 1,310 shares of common stock at $264.35 per share.
• Following these transactions, Patusky directly owns 0 shares of common stock and indirectly owns 1,100 shares through a trust.
• He also directly owns 5,000 stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment about the company's prospects.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies like United Therapeutics.
• Monitoring Form 4 filings is a standard practice for investors to understand the sentiment of company insiders.
• Comparing the volume and frequency of insider transactions with peers such as Gilead Sciences, Amgen, and Biogen can provide insights into relative valuation and management confidence.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect an insider's decision to exercise options and sell shares.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.

Key Dates